PDS Biotech Scheduled to Discuss Q3 Financial Results
PDS Biotechnology Corporation (Nasdaq: PDSB), a pioneering company in the field of immunotherapy, is preparing to host a conference call to share its financial results for the quarter concluding on September 30, 2025. This meeting is a key opportunity for stakeholders and investors to gain insights into the company's performance and direction moving forward. The call is set for Thursday, November 13, 2025, at 8:00 AM Eastern Time, an essential moment for those following the advancements in cancer treatment.
Conference Call Essentials
The details for joining the conference call are straightforward:
- Date: November 13, 2025
- Time: 8:00 AM Eastern Time
- Dial-in Numbers: 1-877-704-4453 for domestic calls and 1-201-389-0920 for international participants.
- Webcast Registration: Interested parties can register to attend the webcast, followed by an option for call-me service 15 minutes before the call begins.
This live session will not only cover financial results but will also include updates about PDS Biotech’s clinical programs, reflecting their ongoing commitment to pioneering cancer therapies.
About PDS Biotechnology
PDS Biotechnology is a cutting-edge immunotherapy company with a mission to revolutionize the approach to targeting and eliminating cancer cells. The firm's lead program is advancing into a pivotal clinical trial aimed at tackling advanced HPV16-positive head and neck squamous cell cancers. Central to this initiative is PDS0101, known as Versamune® HPV, which is being tested alongside established immune checkpoint inhibitors. Furthermore, an innovative combination including PDS01ADC, an IL-12 branded antibody drug conjugate, is being explored across various phase 2 trials against multiple types of cancer.
To learn more about their exciting developments, you can visit their official website, a hub for all the latest news related to their research and innovative work in biotechnology.
Looking Ahead
The upcoming conference call promises to provide stakeholders with critical insights and an understanding of where PDS Biotech stands in achieving its goals within the rapidly evolving landscape of cancer treatment. As they navigate the complexities of clinical trials, their commitment to research and positive outcomes remains steadfast. The event reinforces the company's proactive communication with investors, ensuring transparency regarding their developmental journey.
This discussion will serve as a platform for PDS Biotech to share progress, expectations, and milestones achieved within its clinical operations, fostering trust and engagement with its audience.
Contact Information
Investor Inquiries:
Mike Moyer
LifeSci Advisors
Phone: +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com
Media Inquiries:
David Schull
Russo Partners
Phone: +1 (858) 717-2310
Email: david.schull@russopartnersllc.com
Frequently Asked Questions
What is the main focus of PDS Biotechnology?
PDS Biotechnology focuses on innovative immunotherapy solutions designed to enhance the immune system's ability to target and destroy cancer cells.
When is the conference call scheduled?
The conference call will take place on November 13, 2025, at 8:00 AM Eastern Time.
How can investors join the conference call?
Investors can join the call by dialing in through the provided numbers or by participating in the webcast registration.
What updates will be shared during the call?
The call will provide insights into PDS Biotech’s financial results and updates about their clinical programs.
Where can more information about PDS Biotech be found?
More information can be accessed through the official PDS Biotech website, which contains the latest news and updates about their research.
